The charts of 79 patients who required femoral arterial (FA) thrombectomy after cardiac catheterization were reviewed. Fifteen patients (19%) had poor pulses after thrombectomy and 2 had an extremity amputated. One thousand consecutive patients undergoing cardiac catheterization were also studied to prospectively determine the safety and efficacy of systemic fibrinolytic therapy for treatment of FA thrombosis. Among these, 771 patients underwent retrograde arterial catheterization, including 31 patients with left-sided obstructive lesions who had undergone transarterial balloon dilation procedures with large catheters. All patients were given heparin at the time of arterial cannulation. Patients who had a pulseless extremity 4 hours after catheterization continued to receive heparin therapy for 24 to 48 hours. If the extremity continued to have no palpable pulse and the systolic blood pressure was less than 50% of that in the contralateral leg, intravenous streptokinase infusion was begun. The overall incidence of FA thrombosis was 3.6% (28 of 771), including 39% (12 of 31) of all patients undergoing transarterial balloon dilation procedures; 97% (27 of 28) of patients weighed less than 14 kg and the majority weighed less than 10 kg. After an average treatment period of 33 hours, 16 patients continued to have a pulseless extremity and were treated with streptokinase for an average duration of 13 hours. Normal pulses and systolic blood pressure returned in 14 (88%) and were nearly normal in 1 other patient (6%). The incidence of bleeding at the arterial puncture site was 25% and was highest in the patients who had a transarterial balloon dilation procedure. No serious complications occurred.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0002-9149(86)90075-5 | DOI Listing |
J Clin Med
December 2024
Division of Cardiology, Johns Hopkins University School of Medicine, 600 N Wolfe St, Halsted 500, Baltimore, MD 21287, USA.
Cardiogenic shock (CS) is associated with high mortality, particularly in women. With early intervention being a cornerstone of CS management, this study aims to explore whether sex differences exist in the utilization of critical interventions, timing of treatment, and in-hospital mortality for patients with acute myocardial infarction (AMI) and non-AMI-CS. For this retrospective cohort study, we queried the National Inpatient Sample (years 2016-2021) for CS-related hospitalizations.
View Article and Find Full Text PDFBMC Cardiovasc Disord
January 2025
Department of Cardiology, Changhai Hospital, Naval Medical University, No. 168 Changhai Road, Yangpu District, Shanghai, 200433, China.
Background: Different left atrial appendage closure (LAAC) devices have been introduced into the clinical setting. A new dual-seal mechanism LACbes® occluder with isogenous barbs for LAAC has been designed to facilitate easier delivery and improve safety. The purpose of this study is to compare the clinical outcomes of the WATCHMAN with those of the LACbes® device for LAAC.
View Article and Find Full Text PDFBMC Cardiovasc Disord
January 2025
Department of Cardiology, Peking University International Hospital, Life Park Road No.1, Life Science Park of Zhongguancun, Chang Ping District, Beijing, 102206, China.
Background: The transcatheter edge-to-edge repair (TEER) technique, facilitated by the MitraClip device, is a minimally invasive intervention designed for high-risk patients with mitral regurgitation (MR). This study conducts a retrospective analysis of death events associated with MitraClip implantation over a ten-year decade, utilizing data from the FDA's Manufacturer and User Facility Device Experience (MAUDE) database to evaluate trends in safety outcomes.
Methods: A comprehensive search of the publicly accessible MAUDE database was conducted to retrieve reports of deaths and injuries related to MitraClip implantation from October 2013 to September 2023.
Pediatr Cardiol
January 2025
Department of Pediatrics, Inova Children's Hospital, Fairfax, VA, USA.
Data on outcomes of extracorporeal membrane oxygenation (ECMO) are limited in patients with pulmonary atresia intact ventricular septum (PAIVS). The objective of this study was to describe the use of ECMO and the associated outcomes in patients with PAIVS. We retrospectively reviewed neonates with PAIVS who received ECMO between 2009 and 2019 in 19 US hospitals affiliated with the Collaborative Research for the Pediatric Cardiac Intensive Care Society (CoRe-PCICS).
View Article and Find Full Text PDFRheumatology (Oxford)
January 2025
The Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Objective: To explore the clinical characteristics and risk factors for adverse outcomes in patients with Sjögren's Syndrome-associated pulmonary arterial hypertension (SS-PAH).
Methods: A retrospective analysis was conducted on SS-PAH patients diagnosed by right heart catheterization (RHC) between March 2013 and March 2024 across four Chinese medical centers. Patients were categorized into primary SS-PAH (pSS-PAH) and overlap SS-PAH, based on the presence of additional autoimmune diseases.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!